Down-Staging of EGFR Mutation-Positive Advanced Lung Carcinoma with Gefitinib Followed by Surgical Intervention: Follow-Up of Two Cases

Evgeny V. Levchenko,Vladimir M. Moiseyenko,Dmitry E. Matsko,Aglaya G. Iyevleva,Alexandr O. Ivantsov,Stepan M. Yargnian,Valentin V. Anisimov,Igor I. Semionov,Evgeny N. Imyanitov

Down-Staging of EGFR Mutation-Positive Advanced Lung Carcinoma with Gefitinib Followed by Surgical Intervention: Follow-Up of Two Cases

2009

Evgeny V. Levchenko
Vladimir M. Moiseyenko
Dmitry E. Matsko
Aglaya G. Iyevleva
Alexandr O. Ivantsov
Stepan M. Yargnian
Valentin V. Anisimov
Igor I. Semionov
Evgeny N. Imyanitov

Background: Non-small cell lung carcinomas (NSCLC) carrying a mutation in the epidermal growth factor receptor (EGFR) gene show unprecedented sensitivity to gefitinib or erlotinib.

Keywords:

Adjuvant therapy
Carcinoma
Erlotinib
Gefitinib
Neoadjuvant therapy
General surgery
Epidermal growth factor receptor
Lung cancer
Lung
Medicine
Oncology
Cell
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations